Cargando…

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

BACKGROUND: Patients with borderline resectable pancreatic cancer (BRPC) have poor prognosis with upfront surgery. METHODS: This was a single-arm Phase 2 trial for clinical and biomarker analysis. The primary endpoint is 1-year progression-free survival (PFS) rate. Patients received 8 cycles of neoa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Lee, Sang Soo, Song, Ki Byung, Jeong, Jae Ho, Hyung, Jaewon, Park, Do Hyun, Song, Tae Jun, Seo, Dong Wan, Lee, Sung Koo, Kim, Myung-Hwan, Lee, Seung Soo, Kim, Jin Hee, Jin, Hyung-seung, Park, Jin-hong, Hwang, Dae Wook, Lee, Jae Hoon, Lee, Woohyung, Chang, Heung-Moon, Kim, Kyu-pyo, Ryoo, Baek-Yeol, Kim, Song Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403346/
https://www.ncbi.nlm.nih.gov/pubmed/32433600
http://dx.doi.org/10.1038/s41416-020-0867-x
Descripción
Sumario:BACKGROUND: Patients with borderline resectable pancreatic cancer (BRPC) have poor prognosis with upfront surgery. METHODS: This was a single-arm Phase 2 trial for clinical and biomarker analysis. The primary endpoint is 1-year progression-free survival (PFS) rate. Patients received 8 cycles of neoadjuvant modified (m) FOLFIRINOX. Up to 6 cycles of gemcitabine were given for patients who underwent surgery. Plasma immune cell subsets were measured for analysing correlations with overall survival (OS). RESULTS: Between May 2016 and March 2018, 44 chemotherapy- and radiotherapy-naïve patients with BRPC were included. With neoadjuvant mFOLFIRINOX, the objective response rate was 34.1%, and curative-intent surgery was done in 27 (61.4%) patients. With a median follow-up duration of 20.6 months (95% confidence interval [CI], 19.7–21.6 months), the median PFS and OS were 12.2 months (95% CI, 8.9–15.5 months) and 24.7 months (95% CI, 12.6–36.9), respectively. The 1-year PFS rate was 52.3% (95% CI, 37.6–67.0%). Higher CD14(+) monocyte (quartile 4 vs 1–3) and lower CD69(+) γδ T cell (γδ TCR(+)/CD69(+)) levels (quartiles 1–3 vs 4) were significantly associated with poor OS (p = 0.045 and p = 0.043, respectively). CONCLUSIONS: Neoadjuvant mFOLFIRINOX followed by postoperative gemcitabine were feasible and effective in BRPC patients. Monocyte and γδ T cells may have prognostic implications for patients with pancreatic cancer. ClinicalTrials.gov identifier: NCT02749136.